Evidence map›Paper›PMID 40310264›Full record

ArticleMicrobiology spectrum2025

Genomics-based approach for detection and characterization of SARS-CoV-2 co-infections and diverse viral populations.

Bryan Jimenez-Araya, Aurélie Gourgeon, Mélissa N'Debi, Taylor Thompson, Vanessa Demontant, Axel Simitambe, Michel Lau, Laure Boizeau, Patrice Bruscella, Pierre Cappy and 3 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bryan Jimenez-ArayaTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.ORCID 0009-0006-1962-0666
Aurélie GourgeonDepartment of Virology, Henri Mondor University Hospital (AP-HP), University of Paris-Est, Créteil, France.
Mélissa N'DebiTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.
Taylor ThompsonTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.
Vanessa DemontantGenoBIOMICS platform, Henri Mondor University Hospital (AP-HP), University of Paris-Est, Créteil, France.
Axel SimitambeGenoBIOMICS platform, Henri Mondor University Hospital (AP-HP), University of Paris-Est, Créteil, France.
Michel LauGenoBIOMICS platform, Henri Mondor University Hospital (AP-HP), University of Paris-Est, Créteil, France.
Laure BoizeauTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.
Patrice BruscellaTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.
Pierre CappyTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.
Jean-Michel PawlotskyTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.ORCID 0000-0003-0745-7559
Slim FouratiTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.ORCID 0000-0002-1236-5467
Christophe RodriguezTeam "Viruses, Hepatology, Cancer", INSERM U955 (IMRB), University of Paris-Est, Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the continuous genetic diversification of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) over time, the co-circulation of two different lineages in the same region may lead to co-infections within a host, a situation known to contribute to the emergence of hybrid viral populations through genomic recombination. The aim of this study was to use a genomics-based approach to identify distinct viral populations of SARS-CoV-2 in patients with coronavirus disease 2019 (COVID-19), as an indicator of potential co-infections and recombination events. The cohort included 41,224 serial nasopharyngeal swabs positive for SARS-CoV-2 RNA, prospectively collected between January 2021 and April 2022 as part of the French national surveillance program. Full-length genomes were sequenced by next-generation sequencing (COVIDseq). Intra-host single nucleotide variants (iSNVs) were identified, and a synthetic cohort was generated to establish thresholds of co-infection detection. Eight hundred sixty-one samples with iSNV ratios above the threshold were considered "potential co-infections." Peaks in co-infection prevalence occurred during the periods of co-circulation of different SARS-CoV-2 variants. Co-infection with different Variants of Concern (VoC) was confirmed in 103 cases, including Alpha-Beta in 12 cases, Alpha-Delta in 15 cases, Gamma-Delta in 4 cases, Delta-Omicron in 35 cases, and Omicron BA.1-BA.2 in 37 cases. In conclusion, our study suggests a higher prevalence of SARS-CoV-2 variant/subvariant co-infection events than that previously reported using conventional approaches, particularly during periods characterized by the emergence and co-circulation of multiple lineages, creating an increased risk of recombination. Our results support the premise of the importance of genomics-based approaches to detect co-infection events in virus-infected populations, including co-infection with closely related lineages. IMPORTANCE: We aim to implement an innovative approach to monitor and study the diversity of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) within the human population, particularly during periods of emergence and circulation of VOCs. This approach focused on detecting highly diverse viral samples and co-infection cases, which are known to facilitate viral diversity through recombination and can potentially lead to the emergence of new recombinant lineages with novel characteristics. Monitoring and characterizing co-infection cases during an outbreak is a key strategy for better understanding viral evolution, especially during epidemic periods. However, detecting co-infection cases is challenging, and their prevalence is often highly underestimated. In this study, we developed a strategy to identify highly diverse viral samples that can be implemented in surveillance programs and applied to large datasets. We aim to implement an innovative approach to monitor and study the diversity of SARS-CoV-2 within the human population, particularly during periods of emergence and circulation of Variants of Concern. This approach focused on detecting highly diverse viral samples and co-infection cases, which are known to facilitate viral diversity through recombination and can potentially lead to the emergence of new recombinant lineages with novel characteristics.

Indexed as

CoinfectionCOVID-19GenomicsSARS-CoV-2AdultAgedFemaleFranceGenetic VariationGenome, ViralHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedNasopharynxPhylogenyRNA, Viralco-infectionsnext-generation sequencingSARS-CoV-2viral genomic surveillance

Identifiers

PMID40310264
PMCPMC12131723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.